6 Pro Tips to Avoid MDSAP Non-Conformities

Medical device single audit program (MDSAP) streamlines the audit process for quality management system. MDSAP is a global initiative for a single regulatory audit of the QMS to meet multiple regulatory authorities’ requirements. The regulatory authorities covered are U.S. FDA, Health Canada, Brazil’s ANVISA, Japan’s MHLW/PMDA, and Australia’s TGA. MDSAP will streamline the process and save time and money required for performing different audits for various regulatory agencies. In this blog, we will focus on how to avoid MDSAP non-conformities.

What is MDSAP?

Medical Device Single Audit Program (MDSAP) is a harmonized regulatory framework that enables medical device manufacturers to undergo a single, comprehensive audit of their Quality Management System. This MDSAP QMS audit is accepted by multiple participating authorities. Built on ISO 13485:2016, it integrates country‑specific requirements from regulators in the U.S., Canada, Brazil, Japan, and Australia. Thus, this approach reduces the burden of multiple inspections, strengthens consistency in compliance, and helps manufacturers maintain global market access. Additionally, it ensures patient safety and product quality. The MDSAP certification is recognised by the regulatory authorities of the following countries:

• Canada: Health Canada
• United States: FDA (Food and Drug Administration)
• Brazil: ANVISA (National Health Surveillance Agency)
• Australia: TGA (Therapeutic Goods Administration)
• Japan: PMDA (Pharmaceuticals and Medical Devices Agency)/MHLW (Ministry of Health, Labour and Welfare of Japan)

MDSAP is optional in Australia, Brazil, Japan, and the US. However, January 1st, 2019, onwards MDSAP is a mandatory requirement for class II, III, and IV medical devices in Canada. MDSAP evaluates the manufacturer’s quality management system against ISO 13485 as well as focusses on country-specific regulations. MDSAP certification helps medical device manufacturers efficiently achieve multinational compliance for their device. 

Common MDSAP non‑conformities typically involve weak documentation, poor risk management integration, inadequate supplier controls, and failure to address country‑specific regulatory requirements. These issues are frequently observed during audits and can jeopardize certification if not corrected. Moreover, MDSAP non-conformities can lead to license delays, regulatory penalties, and market access barrier. Hence, it is vital to comply with all the MDSAP requirements.

Structure of the program

• Auditing organizations (AOs): Independent, recognized bodies conduct audits on behalf of regulators. They must be authorized and meet strict competency criteria.
• Framework: Audits are based on ISO 13485:2016 and country‑specific regulatory requirements (FDA, Health Canada, ANVISA, PMDA/MHLW, TGA).
• Global acceptance: A single audit report is shared with all participating regulators, thereby reducing duplication.

MDSAP audit cycle

1. Initial certification audit (Year 1): This is a full evaluation of the manufacturer’s Quality Management System (QMS), conducted in two stages: documentation review and on‑site assessment. Auditors check whether the QMS meets ISO 13485 and country‑specific regulatory requirements. Successful completion results in issuance of the MDSAP certificate, allowing market access in participating regions.
2. Surveillance audits (Years 2 & 3): These are shorter, annual audits designed to verify ongoing compliance and effectiveness of the QMS. They focus on high‑risk processes, such as complaint handling, CAPA, supplier controls, and post‑market surveillance. The goal is to ensure corrective actions are sustained and that no systemic risks have emerged since the initial certification.
3. Recertification audit (End of Year 3): This is a comprehensive reassessment of the entire QMS to confirm long‑term compliance. Auditors review whether the organization has consistently maintained regulatory alignment and quality discipline. Passing this audit renews certification for another three‑year cycle, ensuring continued market access.

4 common MDSAP non-conformities

1. Lack of preparedness for country‑specific requirements: Many companies overlook jurisdiction‑specific rules when preparing QMS documentation, leading to gaps in compliance. Regulators expect explicit references to their national requirements and not just generic ISO 13485 alignment. Missing these details often results in findings during audits and delays in certification.
2. Documentation errors: Auditors frequently identify incomplete or poorly maintained records covering product design, manufacturing, and post‑market activities. Documentation is the backbone of demonstrating conformity, and weak evidence undermines compliance credibility. Disorganized or inaccessible records are one of the most common MDSAP non‑conformities observed.
3. Risk management deficiencies: Risk management must be integrated across design, development, and manufacturing. Many organizations fail to update risk files with post‑market data or link them to CAPA processes. This weak integration exposes systemic risks and is a recurring audit issue. Therefore, risk management deficiencies is one of the major MDSAP non-conformities.
4. Purchase and supply control issues: Companies often lack robust criteria for supplier qualification and monitoring, weakening supply chain reliability. Poor traceability of purchased components can directly affect compliance and patient safety.
5. Weak CAPA and complaint handling: Corrective and Preventive Action (CAPA) systems are often found to be weak, with incomplete root cause analysis or superficial corrective measures. Many organizations delay closing CAPA records or fail to verify whether actions taken were truly effective. Additionally, complaint handling processes may lack proper escalation, tracking, and integration with risk management, leading to repeat findings during audits.

Risks of MDSAP non-conformities

• Certification delays: MDSAP non‑conformities can stall the issuance or renewal of MDSAP certificates. Additionally, it can delay MDL licensing in Canada where MDSAP certification is mandatory for Class II–IV devices. This directly blocks market access and disrupts business continuity.
• Regulatory penalties: Authorities, such as the FDA, may escalate oversight if repeated or critical non‑conformities are found. This can include warning letters, import alerts, or intensified inspections. Such penalties damage credibility and increase compliance costs significantly.
• Market access barriers: Failure to resolve MDSAP non‑conformities can prevent entry into or continuation in participating markets. Distributors and healthcare institutions often require proof of certification for partnerships. Losing certification reduces competitiveness and limits global expansion opportunities.
• Operational disruption: Addressing non‑conformities often requires halting production or diverting resources to corrective actions. This disrupts supply chains and delays product launches.
• Reputational damage: Persistent audit findings signal weak QMS discipline to regulators and stakeholders. This erodes confidence among partners, investors, and healthcare providers. Notably, over time, reputational harm can be more costly than direct regulatory penalties.

How to avoid MDSAP non-conformities? 6 tips

1. Organize and control documentation: Keep all QMS records complete, traceable, and accessible from design history files to post‑market surveillance reports. Auditors expect evidence of conformity. Hence, missing or disorganized documents are a major risk. A strong document control SOP ensures readiness at every stage of the audit.
2. Address country‑specific requirements: Map ISO 13485 processes to each participating regulator’s expectations (FDA complaint handling, Health Canada licensing, ANVISA vigilance, etc.). Explicitly reference these requirements in your QMS documentation rather than relying on generic compliance. This prevents findings related to jurisdictional gaps.
3. Strengthen risk management integration: Maintain updated risk files that link design, manufacturing, and post‑market data. Ensure CAPA processes are tied to risk assessments so corrective actions reduce systemic hazards. Auditors look for risk‑based thinking embedded across all processes and not just in isolated documents.
4. Enhance supplier and purchasing controls: Develop clear criteria for supplier qualification, monitoring, and re‑evaluation.
5. Improve CAPA and complaint handling: Implement SOPs for thorough root cause analysis, timely CAPA closure, and effectiveness verification. Ensure complaint handling systems capture, escalate, and feed data into risk management. This shows regulators that issues are systematically prevented and not just patched.
6. Conduct gap analysis and internal audits: Use the MDSAP audit model and companion documents to simulate auditor expectations. Perform internal audits to identify weaknesses before the official audit. This proactive approach reduces surprises and builds confidence with regulators.

In this blog, we have presented the common MDSAP non-conformities, their risk, and how to avoid them. We at Pharmadocx Consultants offer comprehensive MDSAP certification service to our clients. To avoid the MDSAP certification hurdles and to have a smooth certification journey, drop an email at [email protected] or call/Whatsapp on 9996859227.